Retatrutide for PCOS: Insulin Resistance, Weight and Fertility

Retatrutide PCOS data don't exist yet: as of October 31, 2026, ClinicalTrials.gov lists no retatrutide study in women with polycystic ovary syndrome (PCOS), so nobody can say whether it helps cycles, insulin resistance or fertility in PCOS. What exists is two separate pieces of evidence. Retatrutide causes large weight loss in people with obesity, and older GLP-1 drugs have improved weight, waist size and insulin resistance in small PCOS trials.

The rest of this page keeps those two pieces apart, because mixing them is how a plausible idea turns into a promise. Retatrutide is still investigational, and no approved version exists anywhere.

Is there a retatrutide PCOS trial?

No. We searched ClinicalTrials.gov on October 31, 2026 for retatrutide or its Lilly code LY3437943 alongside polycystic ovary syndrome, PCOS and PMOS, and the search returned zero studies. The registry's full list of retatrutide trials is obesity, type 2 diabetes, kidney, liver, heart, sleep apnea, knee and back pain, and drug-interaction work.

Tirzepatide is slightly ahead. A University of Bonn trial (NCT07326111), a placebo-controlled Phase 4 study planned for about 198 women with overweight or obesity and PCOS-related ovarian dysfunction, started in December 2025. Its primary outcome is improvement in menstrual irregularity over 72 weeks, and the registry estimates a primary completion of December 2028. It's the nearest PCOS answer on the way for this drug class, and it isn't retatrutide.

One naming note. The NHS now calls the condition polyendocrine metabolic ovarian syndrome (PMOS) and says it used to be called PCOS. Most papers and searches still say PCOS, so we do too.

What GLP-1 trials in PCOS actually show

The best pooled data come from a 2023 meta-analysis in BMC Endocrine Disorders (Zhou and colleagues). It combined 11 randomized trials with 840 women who had PCOS and overweight or obesity, lasting 12 to 32 weeks. The drugs were exenatide and liraglutide, the first-generation GLP-1 drugs, alone or with metformin. Semaglutide, tirzepatide and retatrutide weren't in it. This is class evidence, and an old class at that.

Read the last column before the middle one. Weight, waist and HOMA-IR results were consistent across trials. Menstrual regularity was not: an I² of 95.6% means the trials disagreed widely, and the authors point to differing drugs, treatment lengths and lifestyle programs. The natural pregnancy result looks tidy, but the total pregnancy rate wasn't significant and the trials were small and short. The authors themselves call for larger, longer trials, and note few pregnancy-safety data.

Compared with metformin alone, GLP-1 monotherapy wasn't better for free testosterone, DHEAS or the free androgen index in that analysis. The NHS lists metformin, the contraceptive pill and weight loss medicines (if you're overweight) among PMOS treatments, so these are options to discuss together rather than a ladder to climb.

Retatrutide, insulin resistance and weight

Weight first, because that's where retatrutide's data are strongest. In TRIUMPH-1, adults with obesity and no diabetes lost an average of 28.3% of body weight on 12 mg over 80 weeks, against 2.2% on placebo (efficacy estimand, NEJM 2026). That's about 70 lb from a starting weight of 248.5 lb.

None of the published summaries splits those results by PCOS status, and we couldn't find a count of TRIUMPH-1 participants with PCOS. Nobody can tell you the PCOS-specific number.

Insulin resistance is thinner. We found no published HOMA-IR for retatrutide. What exists is indirect:

• In TRANSCEND-T2D-1 (type 2 diabetes, 40 weeks), A1C fell by up to 2.0 points from a baseline of 7.9%, and up to 46% of people reached an A1C under 5.7%, the non-diabetic range (efficacy estimand, Lilly ADA release). 55% of participants were women (Lancet 2026).
• In the Phase 2 obesity trial, Lilly reported exploratory improvements in fasting glucose and insulin at weeks 24 and 48, without giving numbers.
• A Phase 1 study of insulin secretion and sensitivity against semaglutide (NCT06982859) is expected to finish around January 2027, in type 2 diabetes rather than PCOS.

Our read: blood sugar clearly improves on retatrutide, and big weight loss usually improves insulin sensitivity, so a benefit for the insulin-resistance side of PCOS is a reasonable bet. It's still a bet. Women with PCOS can have insulin resistance at normal weight and normal A1C, and no retatrutide trial has measured that group.

Cycles and ovulation

Retatrutide's trials haven't reported on periods, ovulation or androgen levels. The only support for a cycle benefit is the older-GLP-1 data above, with its high heterogeneity, plus the natural pregnancy result in the meta-analysis. The NHS says trouble getting pregnant with PMOS usually comes from the ovaries not releasing an egg each month.

Your cycle is an open question. Periods can also change because of rapid weight loss, stress or a pregnancy, and the pregnancy and fertility page covers the pregnancy side.

Birth control and pregnancy planning

This is where the practical risk sits, and it cuts against the assumption that PCOS makes pregnancy unlikely. The NHS says PMOS can cause trouble getting pregnant, not that pregnancy is ruled out, and the meta-analysis above found more natural pregnancies on GLP-1 drugs.

The pill evidence is class evidence from tirzepatide, not retatrutide. The Zepbound label says a first 5 mg dose lowered peak ethinyl estradiol from a combined pill by 59% and total exposure by 20%, and the label links this to slower stomach emptying. It tells people on oral contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and 4 weeks after each dose increase. Non-oral hormonal methods aren't affected, per the label. The NHS lists the combined pill among PMOS treatments for irregular periods, so this matters here.

Lilly ran a retatrutide pill-interaction study (NCT06039826) in 46 postmenopausal women, completed in July 2024, with no results posted as of October 31, 2026. Retatrutide's trials stepped up every 4 weeks, so if the same logic applied, backup contraception would cover the first 20 weeks of the 12 mg route (the start, plus four dose steps). That's our arithmetic, not a label instruction.

On pregnancy itself: there's no human pregnancy data on retatrutide, and no regulator has set a stop-before-conception interval for it. The Zepbound label says weight loss offers no benefit in pregnancy, may cause fetal harm, and tells people to stop when a pregnancy is recognized. The washout questions, breastfeeding and the tirzepatide evidence are on retatrutide and pregnancy.

Planning to conceive means talking to your prescriber or fertility doctor before starting or while still on treatment. Vials sold online as retatrutide (the retatrutide for sale page explains what's out there) aren't Lilly's product and come with no pregnancy or interaction data of any kind.

What to ask a doctor

If you have PCOS and you're curious about retatrutide, the honest picture is that you'd be asking about an unapproved drug with no PCOS data. The tirzepatide comparison shows what the closest approved drug has done for weight. Questions worth bringing:

1. Is my insulin resistance measured (fasting insulin, HOMA-IR, or a glucose tolerance test), and would metformin make sense first?
2. Which contraception works if I'm on a GLP-1 drug, and for how long after each dose increase?
3. Am I trying to conceive in the next year? If so, how long a gap do I need between the last dose and trying?
4. Is there a trial near me? Lilly's trials list is on ClinicalTrials.gov, but none targets PCOS today.

Side effects are the same as in other groups: nausea, vomiting and diarrhea cluster after dose steps, covered on retatrutide side effects in women. Blood sugar results in type 2 diabetes are on the diabetes page.

The next useful fact is a date: TRIUMPH-5, retatrutide against tirzepatide for weight, has an estimated primary completion of November 2026, and results from the Bonn tirzepatide PCOS trial aren't expected before late 2028.